The scientist who co-created CRISPR isn’t ruling out engineered babies someday
By Antonio Regalado,
MIT Technology Review
| 04. 26. 2022
The day I spoke to Jennifer Doudna was a tough day: the US Patent Office had just ruled against her university on CRISPR’s most important uses, handing the commercial rights to her rivals at the Broad Institute of MIT and Harvard.
Doudna is the co-discoverer of CRISPR editing, the revolutionary method for engineering genes that, 10 years after her original breakthrough, is now making its way into human trials. There’s an expanding list of applications in diagnostics and engineered plants; already researchers are exploring potential treatments to cure sickle cell disease, blindness, and liver disease. In 2020, she shared a Nobel Prize with fellow scientist Emmanuelle Charpentier. The two became the sixth and seventh women to win the award in chemistry.
Doudna heads the Innovative Genomics Institute at the University of California, Berkeley, and the work coming out of her laboratory continues to focus on the molecular details of how the CRISPR system works. Perhaps more than anyone, she has been able to relay to the public the formidable power of versatile gene editing as well as the possible... see more
Related Articles
By John Anderson, The Wall Street Journal | 05.10.2022
“Our Father,” Netflix.
A horror story presented as too much of a horror movie, “Our Father” features interviews with the offspring of fertility doctor Donald Cline, but certainly not all of them. Beginning in 1979, Dr. Cline, by his own...
By Kevin Davies, Genetic Engineering and Biotechnology News | 05.18.2022
WASHINGTON, DC — In his current role as President Biden’s acting scientific advisor, Francis Collins, MD, PhD, is dealing with a wide range of issues from semiconductor shortages to wildfires. “But my heart is in what you are all doing...
By David Jensen, The California Stem Cell Report | 05.20.2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is...
By Joanna Thompson, Scientific American | 05.18.2022
Imagine taking a genetic test that could tell you your personal risk of developing complications and dying from a particular disease, such as cancer, heart attack or even COVID. A version of such a test exists—albeit an imperfect one.
Genome-wide...